Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine for chronic osteoarthritis pain in primary care
NL-OMON42274Phase 3Withdrawn
- Sponsor
- Erasmus MC
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of duloxetine in osteoarthritis (OA) (2 arms), sponsored by Erasmus MC. Primary endpoint: Pain at 3 months. Planned start Feb 2015; status: withdrawn.
02
Drugs
duloxetine
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NL-OMON42274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42274.